triptolid
figur
diterpen
triepoxid
first
isol
medicin
plant
tripterygium
wilfordii
hook
f
twhf
structur
character
follow
year
report
activ
vitro
inhibit
prolifer
induc
apoptosi
variou
cancer
cell
line
prevent
tumor
growth
metastas
recent
triptolid
found
effect
variou
cancer
pancreat
breast
prostat
mechan
action
triptolid
extens
evid
provid
triptolid
coval
modifi
protein
presum
epoxid
ring
open
recent
shown
triptolid
inhibit
atpas
activ
human
xpb
xeroderma
pigmentosum
b
coval
bind
xpb
xpb
part
transcript
factor
thfiih
rna
ii
polymerasemedi
transcript
dna
excis
repair
mani
observ
anticanc
effect
explain
mechan
observ
epigenet
modif
suppress
kinas
triptolid
also
report
first
dctp
pyrophosphatas
interest
note
noncoval
interact
triptolid
target
protein
furthermor
compound
multipl
biolog
activ
could
valu
therapeut
triptolid
report
stimul
channel
open
therebi
restor
calcium
signal
result
attenu
cyst
format
mous
model
polycyst
kidney
also
known
revers
male
antifertil
addit
triptolid
shown
preserv
cognit
function
transgen
mous
model
alzheim
anticanc
activ
triptolid
immunosuppress
antiinflammatori
properti
thoroughli
describ
recent
recent
studi
focu
develop
triptolid
deriv
potenti
antineoplast
despit
promis
bioactiv
poor
aqueou
solubl
dosedepend
toxic
narrow
therapeut
window
lack
patent
protect
triptolid
impedi
preclin
develop
clinic
success
two
earli
stage
clinic
trial
triptolid
potenti
drug
rheumatoid
arthriti
conduct
us
decad
deriv
figur
current
phase
clinic
trial
china
rheumatoid
prodrug
strategi
involv
carboxyl
amino
acid
ester
util
previous
intent
achiev
desir
water
solubl
sever
prodrug
triptolid
report
literatur
triptolid
succin
omtriptolid
figur
one
report
enter
clinic
unfortun
cleavag
prodrug
moieti
slow
incomplet
signific
interpati
variabl
discount
prodrug
strategi
suggest
prodrug
provid
reliabl
releas
triptolid
need
nontox
watersolubl
chemic
stabl
patent
prodrug
approach
would
viabl
option
overcom
physicochem
limit
triptolid
clinic
develop
natur
product
histor
use
phosphat
group
promoieti
success
overcom
numer
deliveri
problem
potenti
prodrug
form
either
direct
linkag
phosphat
moieti
onto
hydroxyl
group
parent
drug
form
phosphomonoest
attach
parent
drug
via
chemic
linker
phosphat
promoieti
ioniz
physiolog
ph
result
signific
increas
aqueou
solubl
poorli
solubl
phenol
alcoholbear
parent
addit
phosphomonoest
prodrug
typic
stabl
long
shelfliv
undergo
alkalin
phosphatas
ec
catalyz
bioconvers
vivo
releas
parent
alcohol
phenol
drug
inorgan
phosphat
numer
phosphomonoest
prodrug
shown
good
convers
parent
drug
presenc
alkalin
phosphatas
aforement
omtriptolid
ineffect
clinic
trial
due
incomplet
slow
bioconvers
hypothes
succin
promoieti
directli
attach
group
triptolid
would
easili
access
enzymat
cleavag
due
steric
crowd
therefor
prerequisit
novel
prodrug
strategi
triptolid
threefold
enhanc
aqueou
solubl
chemic
stabil
fast
complet
bioconvers
vivo
aim
achiev
object
incorpor
phosphonooxymethyl
promoieti
possess
favor
combin
high
aqueou
solubl
chemic
stabil
strategi
success
solubl
enhanc
paclitaxel
propofol
case
promoieti
attach
steric
hinder
hydroxyl
previous
synthesi
evalu
phosphonooxymethyl
deriv
triptolid
figur
pancreat
sever
preclin
cancer
model
describ
improv
synthesi
physicochem
character
pharmacodynam
evalu
human
colon
adenocarcinoma
ovarian
cancer
xenograft
via
intraperiton
oral
rout
use
less
frequent
dose
schedul
employ
previou
studi
initi
attempt
prepar
two
step
triptolid
either
oalkyl
chloromethyl
phosphat
diester
direct
alkyl
hydroxyl
group
chloroiodomethan
therefor
altern
base
methylthiomethyl
hydroxyl
group
select
scheme
furnish
key
intermedi
observ
complet
convers
triptolid
pummer
rearrang
mixtur
product
obtain
product
separ
column
chromatographi
identifi
nmr
target
methylthiomethyl
ether
main
compon
yield
acetoxymethyl
ether
identifi
major
byproduct
yield
triptonid
form
scheme
composit
similar
previous
observ
type
reaction
use
phenylsulfonyl
attempt
carri
basic
hydrolysi
acetoxymethyl
ether
result
decomposit
product
triptolid
could
recov
acid
hydrolysi
yield
altern
approach
scheme
base
treat
triptolid
dimethyl
sulfid
benzoyl
peroxid
acetonitril
result
similar
yield
compound
triptonid
side
product
methodolog
howev
allow
signific
reduct
reaction
time
day
h
also
made
purif
easier
next
step
scheme
convers
methylthiomethyl
ether
dibenzyl
phosphat
achiev
use
niodosuccinimidemedi
ni
nucleophil
displac
dibenzyl
phosphat
presenc
molecular
yield
high
chromatograph
purif
silica
gel
difficult
pronounc
decomposit
due
instabl
benzyl
ester
phosphat
mg
scale
flash
chromatographi
experi
reveal
approxim
degrad
howev
larger
scale
prepar
contact
compound
silica
gel
requir
longer
period
time
degrad
observ
depend
amount
substrat
level
deactiv
silica
gel
attempt
use
altern
sorbent
florisil
alumina
well
triethylamin
deactiv
silica
gel
result
similar
level
degrad
possibl
avoid
purif
prior
hydrogen
due
variou
sulfur
deriv
form
cours
synthesi
compound
even
minut
quantiti
poison
pdc
catalyst
use
benzyl
ether
cleavag
led
increas
catalyt
load
longer
reaction
time
turn
result
larger
number
quantiti
impur
contamin
final
product
addit
format
dibenzyl
phosphat
succinimid
produc
reagent
ni
coelut
column
chromatographi
altern
purif
methodolog
develop
util
sequenc
extract
describ
experiment
section
remov
impur
avoid
product
decomposit
methodolog
proven
reliabl
effici
scalabl
result
remov
sulfur
deriv
succinimid
without
use
chromatograph
purif
penultim
step
dibenzyl
phosphat
subject
hydrogen
presenc
pdc
result
phosphat
convert
treatment
sodium
carbon
final
composit
product
includ
triptolid
result
hydrolysi
final
chemic
step
product
decompos
silica
gel
column
chromatographi
isol
puriti
prepar
hplc
use
column
materi
highli
hygroscop
store
nitrogen
argon
ga
physicochem
character
conduct
assess
solubl
chemic
stabil
adjust
solut
ph
simpl
effect
method
increas
water
solubl
weakli
acid
basic
inject
drug
howev
ph
adjust
viabl
approach
increas
solubl
molecul
triptolid
lack
ioniz
group
compound
variou
strategi
includ
use
cosolv
surfact
complex
agent
exampl
parenter
safe
cyclodextrin
use
overcom
aqueou
solubl
limit
howev
techniqu
contribut
significantli
toxic
ideal
phosphonooxymethyl
prodrug
good
water
solubl
particularli
physiolog
ph
avoid
ph
extrem
andor
cosolv
addit
could
allow
rapid
parenter
infus
without
risk
drug
precipit
use
hplc
aqueou
solubl
buffer
ph
tri
room
temperatur
triptolid
determin
mgml
thu
prodrug
format
solubl
enhanc
time
also
estim
second
dissoci
constant
solut
depend
ph
prodrug
would
exist
diacid
monobas
dibas
state
repres
scheme
limit
pharmaceut
relev
ph
physiolog
accept
solut
would
ensur
ioniz
diacid
speci
howev
signific
given
influenc
aqueou
solubl
chemic
stabil
effect
enzym
substrat
ensur
bioconvers
therefor
within
pharmaceut
relev
ph
rang
would
exist
equilibrium
monobas
dibas
speci
thu
titrat
equilibrium
mixtur
two
speci
provid
acid
ioniz
constant
whose
valu
correspond
inflect
point
estim
use
nmr
advantag
isotop
high
natur
abund
chemic
shift
indic
chang
ioniz
state
phosphoru
nmr
spectrum
obtain
function
ph
experiment
data
shown
chang
observ
phosphoru
chemic
shift
solut
vari
ph
figur
use
determin
eq
experiment
part
ph
depend
observ
chemic
shift
measur
result
sigmoid
curv
typic
titrat
valu
found
compar
favor
estim
ph
would
exist
predominantli
dianion
thu
ensur
high
solubl
follow
oral
dose
prodrug
expos
wide
ph
rang
gi
tract
highli
acid
stomach
neutral
colon
also
wide
array
hydrolyt
enzym
pepsin
pancreatin
present
gi
tract
enzym
natur
function
digest
macromolecul
use
nutrient
also
bind
hydrolyz
drug
compound
therefor
prodrug
must
stabl
acid
basic
enzymat
condit
gi
tract
vivo
oral
dose
excipi
formul
may
also
promot
prodrug
decomposit
therefor
vitro
physiolog
stabil
prodrug
variou
buffer
ph
simul
gastrointestin
fluid
assess
gain
insight
stabil
prodrug
thu
incub
simul
gastric
fluid
sgf
simul
intestin
fluid
sif
variou
buffer
ph
oral
dose
expos
compound
ph
stomach
ph
begin
small
intestin
ph
averag
small
intestin
ph
colon
gastric
empti
time
vari
h
fast
state
sever
hour
heavi
meal
sgf
simul
stomach
fluid
incorpor
acid
enzymat
hydrolysi
condit
sif
mimic
ph
hydrolyt
enzym
intestin
incub
solut
rapid
way
determin
would
stabl
condit
found
gi
tract
compound
demonstr
phdepend
stabil
rapidli
degrad
convers
triptolid
simul
gastric
fluid
low
ph
valu
simul
gastric
fluid
wherea
markedli
stabl
higher
ph
valu
simul
intestin
fluid
tabl
shorter
halflif
low
ph
could
result
acidmedi
remov
promoieti
stomach
howev
protect
stomach
acid
enter
coat
prodrug
natur
tend
less
chemic
stabl
parent
drug
practic
use
prodrug
must
possess
adequ
chemic
stabil
condit
use
prodrug
intend
intraven
administr
exhibit
adequ
solut
state
stabil
readytous
prepar
reason
long
shelf
life
ie
year
formul
solut
state
stabil
inadequ
drug
formul
dri
powder
usual
lyophil
reconstitut
solut
right
administr
exampl
safadi
cowork
describ
develop
phosphonooxymethyl
carbon
novel
watersolubl
prodrug
hinder
alcohol
howev
lack
adequ
chemic
stabil
limit
commerci
clinic
potenti
prodrug
chemic
hydrolysi
follow
ph
neutral
ph
rang
perfectli
suit
formul
deliveri
physiolog
perspect
found
hydrolysi
follow
pseudofirstord
kinet
use
pseudofirstord
rate
constant
determin
sever
temperatur
tabl
arrheniu
plot
drawn
shown
plot
activ
energi
ea
calcul
kjmol
extrapol
plot
lower
temperatur
kobsd
obtain
enabl
calcul
halflif
shelf
life
tabl
thu
chemic
stabil
neutral
ph
found
quit
satisfactori
give
estim
shelf
life
approxim
year
therefor
formul
freezedri
form
aqueou
solut
ph
predict
accept
shelf
life
prerequisit
success
phosphat
prodrug
strategi
convers
catalyz
alkalin
phosphatas
gener
phosphomonoest
phosphonooxymethyl
prodrug
good
substrat
acid
alkalin
phosphatas
found
wide
varieti
live
organ
includ
bacteria
plant
alkalin
phosphatas
found
throughout
bodi
mainli
associ
plasma
membran
intestin
placenta
bone
liver
kidney
high
enzym
particip
hydrolasetransferas
reaction
varieti
phosphatecontain
compound
physiolog
condit
vitro
evalu
dephosphoryl
alkalin
phosphatas
bovin
intestin
mucosa
chosen
impli
name
enzym
maximum
activ
alkalin
region
ph
vitro
assay
phosphat
monoest
prodrug
typic
perform
ph
optimum
ph
activ
alkalin
phosphatas
evalu
bioconvers
kinet
howev
relev
perform
physiolog
ph
thu
chang
ph
reaction
media
may
principl
reduc
catalyt
effici
enzym
howev
proofofconcept
confirm
inde
substrat
alkalin
phosphatas
paramount
clearli
administ
parenter
human
overwhelm
presenc
alkalin
phosphat
vivo
guarante
bioconvers
vitro
enzymat
labil
recent
report
carri
bioconvers
triptolid
presenc
alkalin
phosphatas
glycin
buffer
ph
scheme
exposur
phosphatas
cleav
phosphat
group
releas
hydroxymethyl
deriv
chemic
unstabl
spontan
releas
triptolid
formaldehyd
releas
formaldehyd
prodrug
could
rais
possibl
concern
perceiv
howev
wellknown
turnov
formaldehyd
human
bodi
endogen
formaldehyd
product
normal
metabol
exogen
exposur
exampl
food
rang
g
per
prodrug
releas
milligram
amount
formaldehyd
phosphonooxymethyl
prodrug
per
day
small
amount
formaldehyd
add
littl
baselin
exposur
gram
quantiti
produc
normal
metabol
addit
given
short
halflif
min
formaldehyd
convert
formic
acid
exposur
formaldehyd
produc
prodrug
would
limit
approxim
disappear
format
triptolid
measur
compound
degrad
firstord
process
halflif
determin
min
presenc
alkalin
phosphatas
show
rapid
convers
modifi
drug
parent
compound
addit
found
stabl
h
similar
assay
conduct
absenc
alkalin
phosphatas
short
halflif
assay
indic
enzymat
catalyz
breakdown
occur
fast
rate
short
halflif
consist
hypothesi
methylenelink
phosphat
prodrug
would
releas
rapidli
hamper
steric
hindranc
seen
succin
prodrug
omtriptolid
steric
hindranc
note
bioconvers
number
phosphat
phosphonooxymethyl
previous
report
compound
reduc
tumor
growth
prevent
tumor
progress
improv
surviv
multipl
mous
model
pancreat
efficaci
also
demonstr
preclin
model
osteosarcoma
nonsmal
cell
lung
carcinoma
human
papillomavirusposit
head
neck
squamou
cell
carcinoma
ovarian
studi
evalu
efficaci
daili
intraperiton
ip
administr
use
tumor
xenograft
model
evalu
efficaci
administ
less
frequent
schedul
administ
oral
rout
studi
design
evalu
potenti
efficaci
toxic
administ
ip
daili
qd
rang
dose
administ
variou
schedul
day
anim
model
use
studi
human
colon
adenocarcinoma
cell
line
implant
femal
athym
nude
mice
subcutan
tumor
treatment
group
ten
mice
per
group
includ
four
dose
level
mgkg
five
dose
regimen
treatment
period
daili
qd
week
qd
week
treatment
week
qd
week
treatment
week
week
qd
week
compound
administ
daili
ip
found
effect
reduc
elimin
xenograft
tumor
human
colon
adenocarcinoma
anim
model
dose
level
mgkg
figur
dose
regimen
mgkg
administ
less
frequent
daili
break
daili
dose
also
found
effect
figur
group
receiv
mgkg
daili
week
mgkg
daili
week
follow
mice
surviv
end
studi
respect
tumor
free
compound
gener
well
toler
femal
athym
nude
mice
testarticl
relat
death
observ
mice
receiv
mgkg
dose
least
consecut
day
qd
week
group
qd
week
qd
week
group
clinic
sign
toxic
note
mice
higher
dose
group
day
dose
frequenc
mortal
sever
advers
clinic
sign
escal
dose
level
frequenc
mice
receiv
daili
dose
mgkg
least
mean
group
weight
gain
highest
incid
skin
irrit
necrosi
toward
end
studi
group
receiv
lower
dose
mgkg
intermitt
schedul
fewer
clinic
sign
toxic
higher
weight
gain
cours
studi
studi
design
evalu
efficaci
toler
mous
model
human
ovarian
cancer
administ
via
intraperiton
oral
rout
anim
model
use
studi
human
ovarian
cancer
cell
line
implant
femal
athym
nude
mice
subcutan
tumor
treatment
includ
daili
dose
rang
mgkg
mgkg
ten
mice
per
group
administr
intraperiton
inject
effect
well
toler
femal
athym
nude
mice
subcutan
xenograft
tumor
human
ovarian
carcinoma
daili
dose
mgkg
data
shown
administr
oral
gavag
also
effect
daili
dose
mgkg
slightli
higher
rate
morbid
mortal
figur
frequenc
mortal
sever
advers
clinic
sign
escal
dose
level
two
mice
mgkg
oral
dose
group
surviv
beyond
day
data
shown
clinic
sign
acut
toxic
includ
anorexia
dehydr
moribund
condit
death
vehicl
control
group
mice
euthan
end
studi
tumor
volum
surpass
tumor
volum
end
point
howev
mgkg
mgkg
group
mice
surviv
end
studi
respect
one
group
tumor
free
overcom
solubl
problem
associ
natur
product
disodium
phosphonooxymethyl
prodrug
triptolid
prepar
synthesi
physicochem
character
vivo
efficaci
mous
model
human
colon
adenocarcinoma
human
ovarian
carcinoma
demonstr
suitabl
properti
clinic
candid
synthesi
could
accomplish
three
step
natur
product
scaleup
method
clinic
use
prodrug
pose
problem
chemic
stabil
predict
shelf
life
year
allow
storag
prodrug
extend
time
period
vivo
mous
model
human
colon
adenocarcinoma
human
ovarian
carcinoma
provid
addit
inform
efficaci
toler
suggest
daili
administr
may
requir
may
effect
administ
oral
addit
preclin
safeti
toxic
test
compound
enter
phase
clinic
trial
evalu
advanc
gastrointestin
solut
triptolid
g
mmol
acet
acid
ml
mol
solut
acet
anhydrid
ml
mmol
dmso
ml
mmol
mix
stir
room
temperatur
period
day
reaction
mixtur
pour
water
l
neutral
solid
sodium
bicarbon
ad
portionwis
mixtur
extract
ethyl
acet
ml
combin
organ
extract
dri
anhydr
sodium
sulfat
solvent
remov
reduc
pressur
oili
residu
purifi
flash
chromatographi
ethyl
produc
compound
g
white
foam
nmr
data
match
hrm
calcul
requir
mz
na
found
mz
addit
acetoxymethyl
ether
mg
triptonid
mg
isol
identifi
solut
triptolid
g
mmol
anhydr
acetonitril
ml
dimethyl
sulfid
ml
mmol
equiv
ad
benzoyl
peroxid
g
mmol
equiv
ad
portionwis
cours
h
thereaft
reaction
mixtur
stir
h
dilut
ethyl
acet
ml
wash
dilut
sodium
carbon
satur
ml
brine
ml
dri
sodium
sulfat
overnight
solvent
remov
reduc
pressur
result
viscou
mass
contain
crystal
filter
glass
filter
wash
cold
ethyl
acet
ml
collect
solid
airdri
yield
triptonid
g
filtrat
volum
remov
reduc
pressur
residu
dri
overnight
high
vacuum
produc
g
crude
product
crude
product
purifi
column
chromatographi
silica
gel
use
follow
mixtur
eluent
produc
target
compound
g
addit
amount
triptonid
g
total
yield
triptonid
g
solut
compound
g
mmol
dri
dichloromethan
ml
ad
powder
molecular
siev
g
reaction
mixtur
place
dri
nitrogen
solut
dibenzyl
phosphat
g
mmol
niodosuccinimid
g
mmol
anhydr
tetrahydrofuran
ml
ad
slowli
addit
complet
reaction
mixtur
stir
rt
period
h
filter
dilut
dichloromethan
ml
solut
shaken
thiosulf
ml
fulli
decolor
wash
satur
sodium
bicarbon
ml
brine
ml
organ
solut
dri
sodium
sulfat
h
filter
solvent
remov
reduc
pressur
residu
dissolv
anhydr
acetonitril
ml
solut
extract
pentan
ml
acetonitril
solut
evapor
rotari
evapor
follow
high
vacuum
overnight
dri
yield
g
dibenzyl
ester
use
directli
next
step
without
addit
purif
small
sampl
purifi
silica
gel
flash
chromatographi
etoachexan
give
compound
white
foam
nmr
mhz
j
hz
j
hz
dd
hz
j
hz
j
hz
j
hz
ppm
nmr
mhz
ppm
hrm
calcul
requir
mz
na
found
mz
analyt
hplc
tr
min
l
roundbottom
flask
equip
septa
stir
bar
ad
pdc
g
anhydr
tetrahydrofuran
ml
flask
cool
ice
bath
satur
hydrogen
ga
use
bubbler
stir
full
replac
air
bubbler
remov
solut
dibenzyl
ester
g
mmol
dri
thf
ml
ad
flask
cannula
stir
cool
flask
ice
bath
reaction
mixtur
satur
hydrogen
left
stir
hydrogen
atmospher
h
reaction
mixtur
monitor
tlc
disappear
dibenzyl
ester
complet
reaction
mixtur
purg
nitrogen
filter
pad
celit
thf
solut
cool
ice
cold
solut
anhydr
sodium
carbon
g
mmol
deioniz
water
ml
ad
slowli
stir
keep
temperatur
solvent
remov
rotari
evapor
follow
high
vacuum
evapor
give
slightli
cloudi
aqueou
solut
solut
place
equip
continu
extract
dichloromethan
underw
extract
h
aqueou
solut
separ
extract
ethyl
acet
ml
trace
organ
solvent
remov
rotari
evapor
aqueou
solut
pass
acrodisc
syring
filter
give
clear
aqueou
solut
solut
freezedri
produc
g
product
includ
triptolid
purif
prepar
hplc
elut
methanol
water
provid
pure
colorless
hygroscop
powder
nmr
mhz
j
hz
j
hz
dd
hz
j
hz
j
hz
j
hz
ppm
nmr
mhz
ppm
hrm
calcul
requir
mz
found
mz
approxim
mg
compound
weigh
ml
glass
vial
triplic
ml
tri
buffer
ph
ad
sampl
ml
triptolid
sampl
buffer
solut
satur
triptolid
vial
cap
sonic
vortex
prior
submers
constant
temperatur
shake
bath
shakesmin
maintain
h
time
excess
solid
drug
remov
satur
solut
centrifug
filtrat
clear
filtrat
sampl
appropri
dilut
quantif
hplc
mm
solut
prepar
isoton
solut
prepar
stock
solut
ml
volum
sampl
vari
ph
prepar
ad
small
volum
n
hcl
n
naoh
solut
record
result
ph
denver
instrument
bohemia
ny
aliquot
ml
withdrawn
stock
solut
alter
ph
transfer
nmr
tube
twelv
fifteen
sampl
analysi
prepar
ph
rang
solut
analyz
nmr
spectroscopi
use
mhz
nmr
instrument
chang
chemic
shift
record
function
ph
probe
calibr
use
extern
standard
chemic
shift
solut
depend
ph
dissoci
constant
ka
exist
diacid
monobas
dibas
fraction
shown
scheme
fraction
diacid
fraction
may
ignor
given
low
unlik
ph
solut
within
physiolog
scenario
fraction
monobas
form
fmb
fraction
dibas
form
fdb
therefor
express
eq
h
repres
molar
hydrogen
ion
concentr
observ
chemic
shift
signal
product
mole
fraction
prodrug
speci
multipli
chemic
shift
express
eq
repres
chemic
shift
monobas
dibas
fraction
respect
substitut
eq
give
eq
experiment
data
obtain
indic
shift
chemic
shift
variat
ph
chang
observ
chemic
shift
function
ph
fit
eq
use
graphpad
prism
graph
softwar
version
graphpad
softwar
inc
la
jolla
ca
estim
second
dissoci
constant
mg
amount
dissolv
sodium
chlorid
inject
usp
volum
made
ml
similarli
mg
dissolv
sodium
chlorid
inject
usp
volum
made
ml
two
constitut
high
low
concentr
formul
respect
ampul
steril
ampul
ad
ml
solut
flames
ampul
store
oven
maintain
solut
store
sampl
h
storag
solut
store
sampl
h
storag
solut
store
sampl
day
storag
solut
store
sampl
day
storag
solut
analyz
hplc
describ
experiment
section
simul
gastric
fluid
sgf
fluid
gener
prepar
solut
sodium
chlorid
g
concentr
hcl
ml
pepsin
sigma
g
deioniz
water
ml
final
volum
adjust
ml
addit
deioniz
water
simul
intestin
fluid
sif
fluid
gener
prepar
solut
monobas
potassium
phosphat
g
n
aqueou
sodium
hydroxid
ml
pancreatin
sigma
g
deioniz
water
ml
ph
solut
adjust
addit
n
aqueou
sodium
hydroxid
final
volum
adjust
ml
addit
deioniz
water
sourc
cell
line
tumor
xenograft
cryopreserv
vial
suppli
atcc
human
colorect
adenocarcinoma
cell
line
establish
tumor
tissu
old
adult
femal
cell
grown
monolay
cell
culturetr
dispos
flask
cultur
hyclon
mccoy
cultur
media
supplement
vv
fetal
bovin
serum
origin
vial
thaw
cultur
creat
master
cell
bank
mcb
mcb
vial
test
contamin
mycoplasma
organ
panel
select
rodent
pathogen
confirm
neg
prior
cultur
cell
implant
research
anim
mice
inject
subcutan
right
flank
tumor
cell
solut
unsuppl
mccoy
cultur
medium
volum
ml
use
gaug
needl
human
ovarian
cancer
cell
line
establish
tumor
tissu
untreat
patient
sourc
cell
line
tumor
xenograft
studi
cryopreserv
vial
order
ecacc
european
collect
cell
cultur
via
vendor
sigmaaldrich
cell
grown
monolay
cell
culturetr
dispos
flask
cultur
rpmi
cultur
media
supplement
vv
fetal
bovin
serum
origin
vial
thaw
cultur
creat
mcb
mcb
vial
test
contamin
mycoplasma
organ
panel
select
rodent
pathogen
confirm
neg
prior
cultur
cell
implant
research
anim
mice
inject
subcutan
right
left
flank
tumor
cell
solut
unsuppl
rpmi
cultur
medium
volum
ml
femal
athym
nude
mice
age
week
receiv
tacon
farm
albani
ny
anim
examin
weigh
day
follow
receipt
weight
measur
record
twice
weekli
thereaft
anim
allow
acclim
laboratori
environ
least
day
prior
subcutan
inject
cancer
cell
averag
tumor
volum
random
studi
studi
mice
group
durat
treatment
day
studi
day
studi
dose
concentr
anim
base
averag
bodi
weight
measur
anim
respect
dose
group
carboplatin
dose
studi
mgkg
administ
twice
week
test
articl
formul
usp
salin
deliv
volum
ml
follow
paramet
end
point
evalu
tumor
volum
tumor
volum
chang
tumor
weight
studi
end
clinic
sign
surviv
bodi
weight
bodi
weight
chang
tumor
measur
perform
least
twice
weekli
follow
first
appear
tumor
calibr
digit
calip
use
measur
length
width
tumor
tumor
volum
calcul
formula
l
w
smallest
dimens
record
tumor
volum
tumor
weight
express
mean
sem
